Odds of VTE increased 8.15-fold according to models adjusting for recent hospitalization and steroid exposure<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, June 24, 2021 (HealthDay News) — Patients with inflammatory bowel disease (IBD) who contract severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may have a markedly increased risk for venous thromboembolism (VTE), according to a study published online June 14 in Gastroenterology<\/em>.<\/p>\n Nadim Mahmud, M.D., from the Corporal Michael J. Crescenz VA Medical Center in Philadelphia, and colleagues studied a nationwide cohort of IBD patients to examine the incremental risk for VTE in patients with underlying IBD who contract SARS-CoV-2. All 428 patients with IBD who developed an incident VTE event between April 1, 2020, and March 30, 2021, were included. For each patient, a 30-day window was established prior to VTE and 10 30-day window control periods were generated.<\/p>\n The researchers noted 58 SARS-CoV-2 infections during the study window; 21 occurred within 30 days prior to a VTE. SARS-CoV-2 infection was associated with 8.15-fold increased odds of VTE in models adjusting for recent hospitalization and steroid exposure (95 percent confidence interval, 4.34 to 15.30; P < 0.001). There was no significant association observed between SARS-CoV-2 infection and VTE when limited to patients taking chronic anticoagulation medications (odds ratio, 0.63; 95 percent confidence interval, 0.08 to 5.15; P = 0.66). For patients not previously on anticoagulation, the association was stronger (odds ratio, 14.31; 95 percent confidence interval, 6.90 to 29.66; P < 0.001).<\/p>\n “Our data suggest that IBD patients who contract SARS-CoV-2 have a substantially increased risk of VTE and may therefore benefit from prophylaxis,” the authors write.<\/p>\n Two authors disclosed financial ties to biopharmaceutical and nutrition companies, including Pfizer, which provided an unrestricted research grant to support the study.<\/p>\n